The US Food and Drug Administration provides drug firms with a draft guidance on quality for eye drops and other topical ophthalmic products following a jump the past two years in contamination problems.
Eye Drop Manufacturers Get Advice On Seeing Quality Clearly In US FDA Draft Guidance
Need for guidance shown not only in recalls over past year of OTC eye drops due to bacterial contaminants found in products and insufficient sterility practices in facilities but also in warning letters sent in 2022 and 2023 to firms manufacturing Rx and OTC ophthalmic drugs.
